Pars Plana Vitrectomy Combined With Phacoemulsification Cataract Surgery in Phakic Diabetes Retinopathy Patients

Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04729023
Collaborator
(none)
122
1
2
21.9
5.6

Study Details

Study Description

Brief Summary

Pars plana vitrectomy (PPV) is one of the most widely used surgical therapies to proliferative diabetic retinopathy in the world.

However, as a predictable consequence of PPV surgery, postoperative cataract is observed in 79%-95% of phakic diabetes retinopathy patients after PPV in 6-24 months and a subsequent cataract surgery is usually required. While, the subsequent cataract surgeries not only bring additional economy and workload burden, but also increase the surgical risks. Since the two-step surgical approach has its defects, the combination of PPV and phacoemulsification is an ideal surgical option.

This study is a multi-center prospective study, aimed to evaluate the effect of PPV combined with phacoemulsification cataract surgery in phakic diabetes retinopathy patients, and make a comparation between the combined surgery and the two-step surgery in patients without severe lens opacities.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Pars plana vitrectomy combined with cataract surgery.
  • Procedure: Pars plana vitrectomy with subsequent cataract surgery.
N/A

Detailed Description

The prevalence of diabetes retinopathy is increasing dramatically recent years. Pars plana vitrectomy (PPV) is one of the most widely used surgical therapies to proliferative diabetic retinopathy in the world.

However, as a predictable consequence of PPV surgery, postoperative cataract is observed in 79%-95% of phakic diabetes retinopathy patients after PPV in 6-24 months.Generally, subsequent cataract surgeries are required for the phakic patients within 6-16 months after the PPV surgery to improve visualization. While, the subsequent cataract surgeries not only bring additional economy and workload burden, but also increase the surgical risks because of the deep anterior chamber, zonular dehiscence, and inflammation. Since the two-step surgical approach has its defects, the combination of PPV and phacoemulsification is an ideal surgical option, which is only suggested in patients with severe lens opacities before the PPV surgery so far. For those with mild-moderate lens opacities, the benefits of combined surgery is unknown.

This study is a multi-center prospective study, aimed to evaluate the effect of PPV combined with phacoemulsification cataract surgery in phakic diabetes retinopathy patients, and make a comparation between the combined surgery and the two-step surgery in patients without severe lens opacities.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
122 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effect of Pars Plana Vitrectomy Combined With Phacoemulsification Cataract Surgery in Phakic Diabetes Retinopathy Patients Over 45 Years Old: a Multicenter Randomized Controlled Clinical Study
Actual Study Start Date :
Feb 1, 2021
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Combined surgery group

In this group, all eligible patients will receive pars plana vitrectomy combined with phacoemulsification cataract surgery.

Procedure: Pars plana vitrectomy combined with cataract surgery.
In the combined surgery group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will receive pars plana vitrectomy combined with phacoemulsification and intraocular lens (IOL) implantation at the same time.

Active Comparator: Subsequent surgery group

In this group, all eligible patients will receive pars plana vitrectomy first. And a subsequent phacoemulsification will be systematically performed 6 months after the PPV surgery.

Procedure: Pars plana vitrectomy with subsequent cataract surgery.
In the control group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will first receive pars plana vitrectomy and a subsequent phacoemulsification with IOL implantation will be performed at least 6 month after the PPV.

Outcome Measures

Primary Outcome Measures

  1. Best correct visual acuity (BCVA) [Change from Baseline at 1 week after the surgery(s)]

    BCVA with early treatment diabetic retinopathy study (ETDRS) letters

  2. Best correct visual acuity [Change from Baseline at 1 month after the surgery(s)]

    BCVA with ETDRS letters

  3. Best correct visual acuity [Change from Baseline at 3 months after the surgery(s)]

    BCVA with ETDRS letters

  4. Best correct visual acuity [Change from Baseline at 6 months after the surgery(s)]

    BCVA with ETDRS letters

Secondary Outcome Measures

  1. VFQ-25 score [Change from Baseline at 6 months after the surgery(s).]

    Visual Function Questionnaire-25, values from 0-100, the higher scores mean a better outcome

  2. Complications [through study completion, an average of 1 year]

    Common complications after the surgery like glaucoma, macular edema, iritis, et. al.

  3. Treatment costs [through study completion, an average of 1 year]

    The amount of money paid on the surgery(s) by each patient.

  4. Working delay time [through study completion, an average of 1 year]

    The working delay time due to the surgery(s).

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Proliferative diabetes retinopathy ;

  2. Age over 45 years old;

  3. mild-moderate lens opacities(LOCSⅢ : C3N3P3 or below);

  4. recognition of at least one alphabet in ETDRS chart.

Exclusion Criteria:
  1. Long-standing retinal detachment (more than three months), macular affected

  2. Low Vision or blind on the other eye;

  3. Macular degeneration, including age-related macular degeneration and Polypoidal choroidal vasculopathy;

  4. Ocular trauma;

  5. Glaucoma;

  6. Hereditary retinopathy;

  7. Severe lens opacities before the surgery (LOCSⅢ : C4N4P4 or above).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Zhongshan Ophthalmic center, Sun Yat-sen University Guangzhou Guangdong China 550000

Sponsors and Collaborators

  • Zhongshan Ophthalmic Center, Sun Yat-sen University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Zhongshan Ophthalmic Center, Sun Yat-sen University
ClinicalTrials.gov Identifier:
NCT04729023
Other Study ID Numbers:
  • 2020KYPJ167
First Posted:
Jan 28, 2021
Last Update Posted:
Feb 10, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Zhongshan Ophthalmic Center, Sun Yat-sen University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 10, 2022